GPS2 and breast carcinoma: While this result may be partially explained by the fact that low GPS2 activity is enriched in basal subtypes known to associate with poorer prognosis (Supplementary Figures 5B,C), it is worth noting that lower GPS2 expression in fact correlates with poorer survival in breast cancer patients (Supplemental Figure 5C; Györffy et al., 2010).